Claes Held
A5087154648- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Health and Mental Health
- Atrial Fibrillation Management and Outcomes
- Cardiac Imaging and Diagnostics
- Lipoproteins and Cardiovascular Health
- Coronary Interventions and Diagnostics
- Heart Failure Treatment and Management
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular Function and Risk Factors
- Blood Pressure and Hypertension Studies
- Venous Thromboembolism Diagnosis and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Arrhythmias and Treatments
- Heart Rate Variability and Autonomic Control
- Cardiovascular Health and Risk Factors
- Cardiac electrophysiology and arrhythmias
- GDF15 and Related Biomarkers
- Digital Mental Health Interventions
- Adipokines, Inflammation, and Metabolic Diseases
- Liver Disease Diagnosis and Treatment
- Diabetes Treatment and Management
- EEG and Brain-Computer Interfaces
- Pharmaceutical industry and healthcare
- Cardiovascular and exercise physiology
Uppsala University
2016-2025
LMU Klinikum
2024-2025
Ludwig-Maximilians-Universität München
2024-2025
Uppsala University Hospital
2009-2024
New York University
2024
Karolinska Institutet
2000-2020
NYU Langone Health
2020
Clinical Research Institute
2011-2019
Sociedad Española de Cardiología
2019
Population Health Research Institute
2007-2019
Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and pronounced platelet inhibition than clopidogrel.In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) clopidogrel (300-to-600-mg 75 for prevention cardiovascular events in 18,624 patients admitted to hospital with acute coronary syndrome, or without ST-segment elevation.At 12 months,...
In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter (SGLT2) reduce the risk a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding effects SGLT2 in established failure and reduced ejection fraction, regardless presence or absence diabetes.
Among patients with stable coronary disease and moderate or severe ischemia, whether clinical outcomes are better in those who receive an invasive intervention plus medical therapy than alone is uncertain.
In observational studies, lower homocysteine levels are associated with rates of coronary heart disease and stroke. Folic acid vitamins B6 B12 levels. We assessed whether supplementation reduced the risk major cardiovascular events in patients vascular disease.We randomly assigned 5522 55 years age or older who had diabetes to daily treatment either combination 2.5 mg folic acid, 50 vitamin B6, 1 placebo for an average five years. The primary outcome was a composite death from causes,...
Previous trials have shown that the use of statins to lower cholesterol reduces risk cardiovascular events among persons without disease. Those involved with elevated lipid levels or inflammatory markers and mainly white persons. It is unclear whether benefits can be extended an intermediate-risk, ethnically diverse population
Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia rehospitalization, or urgent revascularization.Follow-up the trial terminated...
Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and those with a systolic blood pressure 160 mm Hg or higher, but its role in at intermediate lower is unclear.In one comparison from 2-by-2 factorial trial, we randomly assigned 12,705 participants who did not have disease to receive either candesartan dose 16 mg per day plus hydrochlorothiazide 12.5 placebo. The first coprimary outcome was composite death causes, nonfatal myocardial infarction,...
Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels this enzyme are associated with an increased risk coronary events. Darapladib is a selective oral inhibitor A2.In double-blind trial, we randomly assigned 15,828 patients stable heart disease to receive either once-daily darapladib (at dose 160 mg) or placebo. The primary end point was composite cardiovascular death, myocardial infarction,...
Background— In the Platelet Inhibition and Patient Outcomes (PLATO) trial, a prespecified subgroup analysis showed significant interaction between treatment region ( P =0.045), with less effect of ticagrelor in North America than rest world. Methods Results— Reasons for were explored independently by 2 statistical groups. Systematic errors trial conduct investigated. Statistical approaches evaluated likelihood play chance. Cox regression analyses performed to quantify how much regional could...
We aimed to investigate the association of number completed races and finishing time with risk arrhythmias among participants Vasaloppet, a 90 km cross-country skiing event. All without cardiovascular disease who Vasaloppet during 1989–98 were followed through national registries until December 2005. Primary outcome was hospitalization for any arrhythmia secondary outcomes atrial fibrillation/flutter (AF), bradyarrhythmias, other supraventricular tachycardias (SVT), ventricular...
Diseases with elevated levels of parathyroid hormone (PTH) such as primary and secondary hyperparathyroidism are associated increased incidence cardiovascular disease death. However, data on the prospective association between circulating PTH mortality in community lacking.The Uppsala Longitudinal Study Adult Men (ULSAM), a community-based cohort elderly men (mean age, 71 years; n=958), was used to investigate plasma mortality. During follow-up (median, 9.7 years), 117 participants died...
Atrial fibrillation (AF) is associated with an increased risk of stroke, which currently estimated by clinical characteristics. The cardiac biomarkers N-terminal fragment B-type natriuretic peptide (NT-proBNP) and troponin high-sensitivity (cTn-hs) are independently stroke in AF. Our objective was to develop validate a new biomarker-based score improve prognostication patients AF.A developed internally validated 14 701 AF levels determined at baseline, median follow-up 1.9 years. Biomarkers...
Impact of changes treatments on outcomes in ST-elevation myocardial infarction (STEMI) patients real-life health care has not been documented. All STEMI cases (n = 105.674) registered the nation-wide SWEDEHEART registry between 1995 and 2014 were included followed for fatal non-fatal up to 20 years. Most treatment occurred from 1994 2008. Evidence-based increased: reperfusion 66.2 81.7%; primary percutaneous coronary intervention: 4.5 78.0%; dual antiplatelet therapy 0 89.6%; statin: 14.1...
AimsMore intense platelet-directed therapy for acute coronary syndrome (ACS) may increase bleeding risk. The aim of the current analysis was to determine rate, clinical impact, and predictors major fatal complications in PLATO study.
The risk of stroke in patients with atrial fibrillation (AF) increases age. In the ARISTOTLE trial, apixaban when compared warfarin reduced rate stroke, death, and bleeding. We evaluated these outcomes relation to patient age.A total 18 201 AF a raised were randomized or 5 mg b.d. dose reduction 2.5 placebo 831 ≥2 following criteria: age ≥80 years, body weight ≤60 kg, creatinine ≥133 μmol/L. used Cox models compare during 1.8 years median follow-up. Of trial population, 30% <65 39% 65 <75,...
Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce events substantially.
Patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events. Whether adding ticagrelor to aspirin improves outcomes in this population is unclear.
Dual antiplatelet therapy reduces non-fatal ischaemic events after acute coronary syndrome (ACS) but increases bleeding to a similar extent. We sought determine the prognostic impact of myocardial infarction (MI) vs. during an extended follow-up period gain insight into trade-off between efficacy and safety among patients ACS. In 12 944 with non-ST-segment elevation ACS from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial, we investigated...
The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use radial-artery access for PCI and administration potent P2Y12 inhibitors without planned glycoprotein IIb/IIIa inhibitors.In this multicenter, randomized, registry-based, open-label clinical trial, we enrolled either ST-segment elevation...
Background Evaluation of cardiovascular prognosis in patients with stable coronary heart disease is based on clinical characteristics and biomarkers indicating dysglycemia, dyslipidemia, renal dysfunction, possibly cardiac dysfunction. Inflammation plays a key role atherosclerosis, but the association between inflammatory outcomes less studied this population. Methods Results Overall, 15 828 STABILITY (Stabilization Atherosclerotic Plaque by Initiation Darapladib Therapy) trial were...